These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36251545)

  • 1. Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary.
    Shubow S; Sun Q; Nguyen Phan AL; Hammell DC; Kane M; Lyman GH; Gibofsky A; Lichtenstein GR; Bloomgarden Z; Cross RK; Yim S; Polli JE; Wang YM
    Clin Pharmacol Ther; 2023 Jan; 113(1):37-49. PubMed ID: 36251545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
    Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
    J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic Biomarkers for Biosimilar Development and Approval: A Workshop Summary.
    Florian J; Sun Q; Schrieber SJ; White R; Shubow S; Johnson-Williams BE; Sheikhy M; Harrison NR; Parker VJ; Wang YM; Strauss DG
    Clin Pharmacol Ther; 2023 May; 113(5):1030-1035. PubMed ID: 36380593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption.
    Hair J; Maryon T; Lieneck C
    Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey.
    Kolbe AR; Kearsley A; Merchant L; Temkin E; Patel A; Xu J; Jessup A
    BioDrugs; 2021 May; 35(3):363-372. PubMed ID: 33826078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives on the Current State of the Biosimilar Regulatory Pathway in the United States.
    Dougherty MK; Zineh I; Christl L
    Clin Pharmacol Ther; 2018 Jan; 103(1):36-38. PubMed ID: 29152721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
    Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
    Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative.
    Edgar BS; Cheifetz AS; Helfgott SM; Smith GP; Bandekar T; Hoye-Simek A; Liu Y; Singh RM; Fajardo KI; Carter J; Simone L
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1129-1135. PubMed ID: 34337986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study.
    Rupert DJ; Jordan AM; Ziemian MA; Brown RM; Fleming NS; Lefebvre RC
    BioDrugs; 2022 Sep; 36(5):645-655. PubMed ID: 35962911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing use and addressing challenges to uptake of biosimilars.
    Leber MB
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology.
    Rodriguez G; Mancuso J; Lyman GH; Cardoso F; Nahleh Z; Vose JM; Gralow JR; Francisco M; Sherwood S
    JCO Oncol Pract; 2023 Jul; 19(7):411-419. PubMed ID: 37027797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic Biomarkers Evidentiary Considerations for Biosimilar Development and Approval.
    Strauss DG; Wang YM; Florian J; Zineh I
    Clin Pharmacol Ther; 2023 Jan; 113(1):55-61. PubMed ID: 36178447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars: Implications for Clinical Practice.
    Rifkin RM; Peck SR
    J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustainable Integration of US Food and Drug Administration-Approved Biosimilars: Pharmacy- Versus Physician-Driven Change.
    Waterhouse DM; Ward P; Drosick DR; Burdette C; Davies D; Mendenhall MA
    JCO Oncol Pract; 2023 Nov; 19(11):1053-1057. PubMed ID: 37738533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
    Whalen J
    Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current market and regulatory landscape of biosimilars.
    Bhatt V
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S451-S456. PubMed ID: 30452213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Status of Biosimilars in Oncology.
    Camacho LH
    Drugs; 2017 Jun; 77(9):985-997. PubMed ID: 28477160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunities and challenges in biosimilar uptake in oncology.
    Dolan C
    Am J Manag Care; 2018 Jun; 24(11 Suppl):S237-S243. PubMed ID: 29957909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rise of biosimilars: How they got here and where they are going.
    Patel D; Gillis C; Naggar J; Mistry A; Mantzoros CS
    Metabolism; 2017 Oct; 75():45-53. PubMed ID: 28939017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.